<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        127-119-22
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZEMITRON 8MG F-C TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ONDANSETRON
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        151.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Arab Pharmaceutical Manufacturing PSC Sult" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Arab Pharmaceutical Manufacturing PSC Sult
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            THE ARAB PHARMACEUTICAL MANUFACTURING PSC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A04AA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zemitron contain a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.</p><p>Zemitron are used for:</p><ul><li>Preventing nausea and vomiting caused by chemotherapy (in adults and children) or radiotherapy for cancer (adults only)</li><li>Preventing nausea and vomiting after surgery (adults only).</li></ul><p>Ask your doctor, nurse or pharmacist if you would like any further explanation about these uses.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Zemitron If:</strong></p><ul><li>You are taking apomorphine (used to treat Parkinson&rsquo;s disease)</li><li>You are allergic (hypersensitive) to ondansetron or any of the other ingredients in Zemitron (listed in section 6).</li></ul><p>If you are not sure, talk to your doctor, nurse or pharmacist before taking Zemitron.</p><p><strong>Warnings and precautions </strong></p><p><em>C</em><em>he</em><em>ck with your doctor, nurse or pharmacist before taking Zemitron if:</em></p><ul><li>You have ever had heart problems (e.g. congestive heart failure which causes shortness of breath and swollen ankles)</li><li>You have an uneven heart beat (arrhythmias)</li><li>You are allergic to medicines similar to ondansetron, such as granisetron or palonosetron</li><li>You have liver problems</li><li>You have a blockage in your gut</li><li>You have problems with the levels of salts in your blood, such as potassium, sodium and magnesium.</li></ul><p>If you are not sure if any of the above apply to you, talk to your doctor, nurse or pharmacist before taking Zemitron.</p><p><strong>Other medicines and Zemitron</strong></p><p>Please tell your doctor, nurse or pharmacist if you are taking or have recently taken or might take other medicines. This includes medicines that you buy without a prescription and herbal medicines. This is because Zemitron can affect the way some medicines work. Also some other medicines can affect the way Zemitron works.</p><p><em>I</em><em>n particular, tell your doctor, nurse or pharmacist if you are taking any of the following medicines:</em></p><ul><li>Carbamazepine or phenytoin used to treat epilepsy</li><li>Rifampicin used to treat infections such as tuberculosis (TB)</li><li>Antibiotics such as erythromycin or ketoconazole</li><li>Anti-arrhythmic medicines used to treat an uneven heart beat</li><li>Beta-blocker medicines used to treat certain heart or eye problems, anxiety or prevent migraines</li><li>Tramadol, a pain killer</li><li>Medicines that affect the heart (such as haloperidol or methadone)</li><li>Cancer medicines (especially anthracyclines and trastuzumab)</li><li>SSRIs (selective serotonin reuptake inhibitors) used to treat depression and/or anxiety including fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram</li><li>SNRIs (serotonin noradrenaline reuptake inhibitors) used to treat depression and/or anxiety including venlafaxine, duloxetine.</li></ul><p>If you are not sure if any of the above applies to you, talk to your doctor, nurse or pharmacist before having Zemitron.</p><p><strong>Pregnancy and breast feeding</strong></p><p>You should not use ondansetron during the first trimester of pregnancy. This is because ondansetron can slightly increase the risk of a baby being born with cleft lip and/or cleft palate (openings or splits in the upper lip and/or the roof of the mouth). If you are already pregnant, think you are might be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking ondansetron.</p><p>If you are a woman of childbearing potential you may be advised to use effective contraception.</p><p>Ondansetron is not to be used for the treatment of nausea and vomiting in pregnancy.</p><p>If a woman becomes pregnant while using ondansetron, pregnancy will have to be closely monitored taking into account the risk of congenital malformations.</p><p>Physicians must inform women who clinically require ondansetron treatment about the potential risks of birth defects associated with use during pregnancy.</p><p>Do not breast-feed if you are taking ondansetron. This is because small amounts pass into the mother&rsquo;s milk. Ask your doctor for advice.</p><p><strong>Zemitron contains lactose</strong> <strong>monohydrate and sodium</strong></p><p>Zemitron contains lactose monohydrate. Each film-coated tablet of Zemitron 4 mg and 8 mg Film-coated Tablets contains 23.9 mg or 47.8 mg lactose monohydrate; respectively. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>Zemitron contains sodium. Each film-coated tablet of Zemitron 4 mg and 8 mg Film-coated Tablets contains 0.0875 mg or 0.175 mg sodium; respectively. This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Zemitron exactly as your doctor has told you. You should check with your doctor, nurse or pharmacist if you are not sure. The dose you have been prescribed will depend on the treatment you are having.</p><p><strong>To prevent nausea and vomiting from chemotherapy or radiotherapy</strong></p><p><em>O</em><em>n the day of chemotherapy or radiotherapy:</em></p><ul><li>The usual adult dose is 8 mg taken one to two hours before treatment and another 8 mg twelve hours after<strong>.</strong></li></ul><p><em>O</em><em>n the following days:</em></p><ul><li>The usual adult dose is 8 mg twice a day</li><li>This may be given for up to 5 days.</li></ul><p><em>Children </em><em>aged over 6 months and adolescents:</em></p><p>The doctor will decide the dose depending on the child&rsquo;s size (body surface area) or weight.</p><ul><li>The usual dose for a child is up to 4 mg twice a day</li><li>This can be given for up to 5 days.</li></ul><p><strong>To prevent nausea and vomiting after an operation</strong></p><p>The usual adult dose is 16 mg before your operation</p><p><em>Children aged over 1 month and adolescents:</em></p><ul><li>It is recommended that ondansetron is given as an injection.</li></ul><p><strong>Patients with moderate or severe liver problems</strong></p><p>The total daily dose should not be more than 8 mg.</p><p>Zemitron should start to work within one or two hours of taking a dose.</p><p><strong>If you are sick (vomit) within one hour of taking a dose</strong></p><ul><li>Take the same dose again</li><li>Otherwise, do not take more Zemitron than prescribed.</li></ul><p>If you continue to feel sick, tell your doctor or nurse.</p><p><strong>If you take more Zemitron than you should</strong></p><p>If you or your child take more Zemitron than you should, talk to a doctor or go to a hospital straight away. Take the medicine pack with you.</p><p><strong>If you forget to take Zemitron</strong></p><p><em>I</em><em>f you miss a dose and<strong> </strong>feel sick or vomit:</em></p><ul><li>Take Zemitron as soon as possible, then</li><li>Take your next tablet at the usual time</li><li>Do not take a double dose to make up for a forgotten dose.</li></ul><p><em>I</em><em>f you miss a dose but do not feel sick:</em></p><ul><li>Take the next dose at the usual time</li><li>Do not take a double dose to make up for a forgotten dose.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Zemitron tablets can cause side effects, although not everybody gets them.</p><p><strong>A</strong><strong>ll</strong><strong>ergic reactions</strong></p><p>If you have an allergic reaction, stop taking it and see a doctor straight away. The signs may include:</p><ul><li>Sudden wheezing and chest pain or chest tightness</li><li>Swelling of your eyelids, face, lips, mouth or tongue</li><li>Skin rash - red spots or lumps under your skin (hives) anywhere on your body</li><li>Collapse.</li></ul><p><strong><em>O</em></strong><strong><em>ther side effects include:</em></strong></p><p><strong>Very common (may affect more than 1 in 10 people)</strong></p><ul><li>Headache.</li></ul><p><strong>C</strong><strong>ommon (may affect up to 1 in 10 people)</strong></p><ul><li>A feeling of warmth or flushing</li><li>Constipation</li><li>Changes to liver function test results (if you take ondansetron tablets with a medicine called cisplatin, otherwise this side effect is uncommon).</li></ul><p><strong>U</strong><strong>ncommon (may affect up to 1 in 100 people)</strong></p><ul><li>Hiccups</li><li>Low blood pressure, which can make you feel faint or dizzy</li><li>Uneven heart beat</li><li>Chest pain</li><li>Fits</li><li>Unusual body movements or shaking.</li></ul><p><strong>R</strong><strong>are (may affect up to 1 in 1,000 people)</strong></p><ul><li>Feeling dizzy or light headed</li><li>Blurred vision</li><li>Disturbance in heart rhythm (sometimes causing a sudden loss of consciousness).</li></ul><p><strong>Very rare (may affect up to 1 in 10,000 people)</strong></p><ul><li>Poor vision or temporary loss of eyesight, which usually comes back within 20 minutes.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store in a dry place below 30&deg;C.</p><p>Store in the original package.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient is ondansetron hydrochloride dihydrate.</p><p>Each film-coated tablet of Zemitron 4 mg Film-coated Tablets contains 5.1 mg ondansetron hydrochloride dihydrate equivalent to 4 mg ondansetron.</p><p>Each film-coated tablet of Zemitron 8 mg Film-coated Tablets contains 10.2 mg ondansetron hydrochloride dihydrate equivalent to 8 mg ondansetron.</p><p>The other ingredients are lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, hydroxypropyl methyl cellulose, titanium dioxide, pigment blend yellow (only in Zemitron 8 mg Film-coated Tablets) and yellow iron oxide (only in Zemitron 8 mg Film-coated Tablets).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zemitron 4 mg Film-coated Tablets are white to off-white compact biconvex round film-coated tablets of smooth surface, embossed with “A7” on one side in aluminum-aluminum blisters. 

Zemitron 8 mg Film-coated Tablets are yellow compact biconvex round film-coated tablets of smooth surface, embossed with “A5” on one side in aluminum-aluminum blisters.

Pack size: 10 Film-coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder </strong><strong>and </strong><strong>Manufacturer</strong></p><p>The Arab Pharmaceutical Manufacturing PSC</p><p>P.O. Box 42</p><p>Sult, Jordan</p><p>Tel: + (962-5) 3492200</p><p>Fax: + (962-5) 3492203</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>&nbsp; &nbsp; Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>&nbsp; &nbsp; Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 05/2021; version number SA2.2.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي زيمترون على دواء يسمى أوندانسيترون. ينتمي هذا الدواء إلى مجموعة الأدوية التي تسمى مضادات القيء.</p><p dir="RTL">يستخدم زيمترون من أجل:</p><ul dir="rtl"><li>منع الغثيان والقيء الناتجان عن العلاج الكيميائي (عند البالغين والأطفال) أو العلاج الإشعاعي لعلاج السرطان (عند البالغين فقط)</li><li>منع الغثيان والقيء بعد العملية الجراحية (عند البالغين فقط).</li></ul><p dir="RTL">إذا كنت تريد المزيد من التوضيح حول هذه الاستخدامات، اسأل طبيبك، الممرض أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول </strong><strong>زيمترون إذا</strong><strong>:</strong></p><ul dir="rtl"><li>كنت تتناول آبومورفين (يستخدم لعلاج مرض الباركنسون)</li><li>كنت تعاني من الحساسية (فرط الحساسية) لأوندانسيترون أو لأي من المواد الأخرى المستخدمة في تركيبة زيمترون (المذكورة في القسم 6).</li></ul><p dir="RTL">تحدث مع طبيبك، الممرض أو الصيدلي قبل القيام بتناول زيمترون، إذا لم تكن متأكداً.</p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL"><em>تحقق مع طبيبك، الممرض أو الصيدلي قبل القيام بتناول </em><em>زيمترون</em><em> </em><em>إذا: </em></p><ul dir="rtl"><li>سبق وعانيت من مشاكل في القلب (مثل فشل القلب الاحتقاني الذي يسبب ضيق النفس وتورم الكاحلين)</li><li>كنت تعاني من نبضات غير منتظمة للقلب (اضطرابات نظم القلب)</li><li>كنت تعاني من الحساسية للأدوية المشابهة لأوندانسيترون، مثل غرانيسيترون أو بالونوسيترون</li><li>كنت تعاني من مشاكل في الكبد</li><li>كنت تعاني من انسداد معوي</li><li>كنت تعاني من مشاكل في مستويات الأملاح في دمك، مثل البوتاسيوم، الصوديوم والمغنيسيوم.</li></ul><p dir="RTL">تحدث إلى طبيبك، الممرض أو الصيدلي قبل القيام بتناول زيمترون، إذا لم تكن متأكدا إذا كان أي مِما سبق ينطبق عليك.</p><p dir="RTL"><strong>الأدوية الأخرى وزيمترون </strong></p><p dir="RTL">الرجاء إخبار طبيبك، الممرض أو الصيدلي إذا كنت تتناول، أو تناولت مؤخراً أو قد تتناول أية أدوية أخرى. يتضمن هذا الأدوية التي تقوم بشرائها من غير وصفة طبية والأدوية العشبية. هذا لأن زيمترون قد يؤثر على طريقة عمل بعض الأدوية. أيضاً قد تؤثر بعض الأدوية على طريقة عمل زيمترون.</p><p dir="RTL"><em>على وجه الخصوص، أخبر طبيبك، الممرض أو الصيدلي إذا كنت تتناول أي من الأدوية التالية: </em></p><ul dir="rtl"><li>الكاربامازيبين أو الفينيتوين اللّذان يستخدمان لعلاج الصَّرْع</li><li>الريفامبيسين الذي يستخدم لعلاج العدوى مثل <strong>ا</strong>لسل</li><li>المضادات الحيوية مثل إيريثروميسين أو كيتوكونازول</li><li>الأدوية المضادة لاضطراب نظم القلب التي تستخدم لعالج النبضات الغير منتظمة للقلب</li><li>أدوية حاصرات البيتا المستخدمة لعلاج مشاكل معينة في القلب أو العين، القلق أو منع الشقيقة<strong> </strong></li><li>الترامادول، مسكن للألم</li><li>الأدوية التي تؤثر على القلب (مثل هالوبيريدول أو ميثادون)</li><li>أدوية علاج السرطان (خاصة الأَنثراسيكلين والتراستوزماب)</li><li>مثبطات استرداد السيريتونين الانتقائية التي تستخدم لعلاج الاكتئاب و/أو القلق من ضمنها فلوكسيتين، باروكسيتين، سيرترالين، فلوفوكسامين، سيتالوبرام، إيسيتالوبرام</li><li>مثبطات استرداد السيريتونين والنورإيبينيفرين التي تستخدم لعلاج الاكتئاب و/أو القلق من ضمنها فانلافاكسين، دولوكستين.</li></ul><p dir="RTL">تحدث إلى طبيبك، الممرض أو الصيدلي قبل القيام بتناول زيمترون إذا لم تكن متأكدا إذا كان أي من ما سبق ينطبق عليك.</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">لا يجب استخدام أوندانسيترون خلال الثلث الأول من الحمل. هذا لأن أوندانسيترون يمكن أن يزيد قليلاً من خطورة ولادة الطفل بشفة مشقوقة و/أو حنك مشقوق (فتحات أو تفككات في الشفة العليا و/أو سقف الفم).</p><p dir="RTL">قومي بطلب النصيحة من طبيبكِ أو الصيدلي قبل القيام بأخذ أوندانسيترون، إذا كنتِ حاملاً بالفعل، تعتقدين بأنك حاملاً أو تخططين لذلك.</p><p dir="RTL">إذا كنتِ امرأة قادرة على الإنجاب قد تُنصحين باستخدام وسائل منع حمل فعالة.</p><p dir="RTL">يجب عدم استخدام أوندانسيترون لعلاج الغثيان والقيء خلال الحمل.</p><p dir="RTL">إذا أصبحت المرأة حاملاً أثناء استخدام أوندانسيترون، سيتم مراقبة الحمل بعناية مع الأخذ بعين الاعتبار خطورة التشوه الخلقي الجنيني.</p><p dir="RTL">يجب على الطبيب الممارس إبلاغ النساء اللواتي يتطلب علاجهم سريرياً بالأوندانسيترون بمخاطر التشوهات الخلقية المحتملة المصاحبة للاستخدام خلال الحمل.</p><p dir="RTL">لا ترضعي طفلك إذا قمتِ بأخذ أوندانسيترون. هذا لأن كميات قليلة منه تنتقل إلى حليب الأم. قومي بطلب النصيحة من طبيبكِ.</p><p dir="RTL"><strong>يحتوي زيمترون على اللاكتوز</strong><strong> أحادي الماء</strong><strong> والصوديوم</strong></p><p dir="RTL">يحتوي زيمترون على اللاكتوز<strong> </strong>أحادي الماء. يحتوي كل قرص مغطى بطبقة رقيقة من زيمترون ٤ ملغم و٨ ملغم أقراص مغطاة بطبقة رقيقة على ٢٣,٩ ملغم أو ٤٧,٨ ملغم لاكتوز أحادي الماء؛ على التوالي. إذا تم إخبارك من قِبل طبيبك أن لديك عدم تحمل لبعض أنواع السكريات، تواصل مع طبيبك قبل تناول هذا المستحضر الدوائي.</p><p>يحتوي زيمترون على الصوديوم. يحتوي كل قرص مغطى بطبقة رقيقة من زيمترون ٤ ملغم و٨ ملغم أقراص مغطاة بطبقة رقيقة على ٠,٠٨٧٥ ملغم أو ٠,١٧٥ ملغم صوديوم؛ على التوالي. يحتوي هذا الدواء على أقل من ١ ملمول صوديوم (٢٣ ملغم) لكل قرص مغطى بطبقة رقيقة، فيمكن اعتباره أنه &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائماً قم بتناول دوائك كما وصفه لك طبيبك أو الصيدلي تماماً. تحقق من طبيبك، الممرض أو الصيدلي إذا لم تكن متأكداً. ستعتمد جرعتك الموصوفة على العلاج الذي تخضع له.</p><p dir="RTL"><strong>لمنع الغثيان والقيء الناتجان من العلاج الكيميائي أو </strong><strong>العلاج</strong><strong> </strong><strong>الإشعاعي</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>البالغين</strong></p><p dir="RTL"><em>في يوم موعد أخذ العلاج الكيميائي أو </em><em>العلاج</em><em> </em><em>الإشعاعي:</em></p><ul dir="rtl"><li>جرعة البالغين الاعتيادية هي ٨ ملغم يتم تناولها قبل بساعة أو ساعتين من العلاج و٨ ملغم أخرى بعد ١٢ ساعة.</li></ul><p dir="RTL"><em>في الأيام التالية:</em></p><ul dir="rtl"><li>الجرعة الاعتيادية للبالغين هي ٨ ملغم مرتين في اليوم</li><li>قد يتم إعطاء هذه الجرعة لمدة ٥ أيام.</li></ul><p dir="RTL"><em>الأطفال الذين تزيد أعمارهم عن ٦ أشهر والمراهقون:</em></p><p dir="RTL">سوف يقرر الطبيب الجرعة إعتماداً على حجم الطفل (مساحة سطح الجسم) أو وزنه.</p><ul dir="rtl"><li>الجرعة الاعتيادية للطفل تصل إلى ٤ ملغم مرتين في اليوم</li><li>يمكن إعطاء هذه الجرعة لمدة ٥ أيام.</li></ul><p dir="RTL"><strong>لمنع وعلاج الغثيان والقيء الناتجان بعد العملية الجراحية </strong></p><p dir="RTL">الجرعة الاعتيادية للبالغين هي ١٦ ملغم قبل العملية</p><p dir="RTL"><em>الأطفال الذين تزيد أعمارهم عن شهر واحد والمراهقون:</em></p><ul dir="rtl"><li>يوصى بإعطاء أوندانسيترون على شكل حقنة.</li></ul><p dir="RTL"><strong>المرضى الذين يعانون من مشاكل متوسطة أو شديدة في الكبد </strong></p><p dir="RTL">يجب ألا تتجاوز الجرعة الكلية اليومية ٨ ملغم.</p><p dir="RTL">يبدأ مفعول زيمترون خلال ساعة او ساعتين من تناول الجرعة.&nbsp;</p><p dir="RTL"><strong>إذا تقيأت خلال ساعة واحدة من تناول الجرعة</strong></p><ul dir="rtl"><li>تناول نفس الجرعة مرة أخرى</li><li>خلاف ذلك، لا تتناول زيمترون أكثر من الجرعة الموصوفة.</li></ul><p dir="RTL">إذا استمر شعورك بالتقيؤ، أخبر طبيبك أو الممرض.</p><p dir="RTL"><strong>إذا تناولت زيمترون أكثر من اللازم</strong></p><p dir="RTL">إذا تناولت أنت أو طفلك زيمترون أكثر مما ينبغي، تحدث مع طبيبك أو اذهب إلى المستشفى مباشرة. خذ علبة الدواء معك.</p><p dir="RTL"><strong>إذا نسيت تناول زيمترون</strong></p><p dir="RTL"><em>إذا نسيت تناول جرعة وكنت تشعر با</em><em>لغثيان أ</em><em>و التقيؤ:</em></p><ul dir="rtl"><li>تناول زيمترون بأسرع وقت ممكن، بعد ذلك</li><li>تناول القرص التالي في الوقت المعتاد</li><li>لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</li></ul><p dir="RTL"><em>إذا نسيت تناول جرعة لكن لا تكن تشعر بالغثيان:</em></p><ul dir="rtl"><li>تناول الجرعة التالية في الوقت المعتاد</li><li>لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب زيمترون آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><strong>ردود الفعل التحسسية</strong></p><p dir="RTL">إذا كان لديك رد فعل تحسسي، توقف عن تناول هذا الدواء واذهب لرؤية طبيب على الفور. قد تشمل الأعراض:</p><ul dir="rtl"><li>صفير مفاجىء وألم في الصدر أو ضيق في الصدر</li><li>تورم الجفون، الوجه، الشفاه، الفم أو اللسان</li><li>طفح جلدي - بقع حمراء أو كتل تحت الجلد (الشرى) في أي مكان في جسمك</li><li>هبوط.</li></ul><p dir="RTL"><strong><em>آثار جانبية أخرى:</em></strong></p><p dir="RTL"><strong>شائعة</strong><strong> </strong><strong>جداً</strong><strong> (</strong><strong>قد تؤثر على أكثر من شخص</strong><strong> </strong><strong>من كل </strong><strong>١٠&nbsp;</strong><strong>أشخاص)</strong></p><ul dir="rtl"><li>صداع.</li></ul><p dir="RTL"><strong>شائعة (</strong><strong>قد تؤثر على ما يصل إلى شخص واحد من كل ١٠ أشخاص)</strong></p><ul dir="rtl"><li>الشعور بالدفء أو التورّد</li><li>الإمساك</li><li>تغيّر في نتائج اختبار وظائف الكبد (إذا كنت تتناول أقراص أوندانسيترون مع دواء يسمى سيسبلاتين، غير ذلك، تعتبر من الآثار الجانبية الغير شائعة).</li></ul><p dir="RTL"><strong>غير شائعة (قد تؤثر على ما يصل إلى شخص</strong><strong> </strong><strong>من كل </strong><strong>١٠٠&nbsp;</strong><strong>شخص)</strong></p><ul dir="rtl"><li>الفواق</li><li>انخفاض ضغط الدم، الذي بإمكانه أن يؤدي إلى شعورك بالإغماء أو الدوخة</li><li>نبضات قلب غير منتظمة</li><li>ألم في الصدر</li><li>نوبات تشنجية</li><li>حركات غير اعتيادية للجسم أو الرجفان.</li></ul><p dir="RTL"><strong>نادرة (قد تؤثر على ما يصل إلى شخص</strong><strong> </strong><strong>من كل </strong><strong>١٠٠٠&nbsp;</strong><strong>شخص)</strong></p><ul dir="rtl"><li>الشعور بالدوخة أو الدوار</li><li>تغيم الرؤية</li><li>اضطرابات في نظم القلب (مما قد يؤدي في بعض الأحيان إلى فقدان وعي مفاجىء).</li></ul><p dir="RTL"><strong>نادرة جداً (قد تؤثر على ما يصل إلى شخص</strong><strong> </strong><strong>من بين كل </strong><strong>١٠٠٠٠</strong><strong> </strong><strong>شخص)</strong></p><ul dir="rtl"><li>رؤية سيئة أو فقدان مؤقت للبصر، الذي يعود خلال ٢٠ دقيقة في العادة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ في مكان جاف عند درجة حرارة أقل من ٣٠&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p>لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي هيدروكلوريد الأوندانسيترون ثنائي الماء.</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة من زيمترون ٤ ملغم أقراص مغطاة بطبقة رقيقة على ٥,١ ملغم هيدروكلوريد الأوندانسيترون ثنائي الماء يكافئ ٤ ملغم أوندانسيترون.</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة من زيمترون ٨ ملغم أقراص مغطاة بطبقة رقيقة على ١٠,٢ ملغم هيدروكلوريد الأوندانسيترون ثنائي الماء يكافئ ٨ ملغم أوندانسيترون.</p><p>المواد الأخرى المستخدمة في التركيبة التصنيعية هي لاكتوز أحادي الماء، سيلليلوز بلوري مكروي، جلايكولات نشا الصوديوم، ستيرات المغنيسيوم، هيدروكسي بروبيل ميثيل السيلليلوز، ثاني أكسيد التيتانيوم، مزيج الصباغ الأصفر (فقط في زيمترون ٨ ملغم أقراص مغطاة بطبقة رقيقة) وأكسيد الحديد الأصفر (فقط في زيمترون ٨ ملغم أقراص مغطاة بطبقة رقيقة).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">زيمترون ٤ ملغم أقراص مغطاة بطبقة رقيقة هي أقراص بيضاء مائلة إلى الأبيض المصفر مضغوطة دائرية محدبة الوجهين مغطاة بطبقة رقيقة ذات سطح أملس، منقوش عليها &quot;A7&quot; على أحد الوجهين في أشرطة من الألمنيوم-الألمنيوم.</p><p dir="RTL" style="text-align:right">زيمترون ٨ ملغم أقراص مغطاة بطبقة رقيقة هي أقراص صفراء مضغوطة دائرية محدبة الوجهين مغطاة بطبقة رقيقة ذات سطح أملس، منقوش عليها &quot;A5&quot; على أحد الوجهين في أشرطة من الألمنيوم-الألمنيوم.</p><p dir="RTL" style="text-align:right">حجم العبوة: ١٠ أقراص مغطاة بطبقة رقيقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق والشركة المصنعة</strong></p><p dir="RTL">الشركة العربية لصناعة الأدوية المساهمة الخاصة</p><p dir="RTL">صندوق بريد ٤٢</p><p dir="RTL">السلط، الأردن</p><p dir="RTL">هاتف: ٣٤٩٢٢٠٠ (٥-٩٦٢) +</p><p dir="RTL">فاكس: ٣٤٩٢٢٠٣ (٥-٩٦٢) +</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul><li dir="RTL">&nbsp; &nbsp; المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul><li dir="RTL">&nbsp; &nbsp; دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ ٢٠٢١/٠٥ ؛ رقم النسخة SA2.2.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zemitron 8 mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 10.2 mg ondansetron hydrochloride dihydrate equivalent to 8 mg ondansetron.

Excipient(s) with known effect: Lactose monohydrate and sodium.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.

Yellow compact biconvex round film-coated tablets of smooth surface, embossed with “A5” on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adults:</strong></p><p>Zemitron is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.</p><p>Zemitron is indicated for the prevention of post-operative nausea and vomiting (PONV). For treatment of established PONV, administration by injection is recommended.</p><p><strong>Paediatric Population:</strong></p><p>Zemitron is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged &ge; 6 months.</p><p>No studies have been conducted on the use of orally administered ondansetron in the prevention and treatment of PONV in children aged &ge; 1 month, administration by IV injection is recommended for this purpose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Posology </em></strong></p><p><strong>Chemotherapy and radiotherapy induced nausea and vomiting (CINV and RINV)</strong></p><p><u>Adults:</u></p><p>The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The selection of dose regimen should be determined by the severity of the emetogenic challenge.</p><p><em>Emetogenic chemotherapy and radiotherapy:</em>&nbsp;Ondansetron can be given either by rectal, oral (tablets or syrup), intravenous or intramuscular administration.</p><p>The recommended oral dose is 8 mg taken 1 to 2 hours before chemotherapy or radiation treatment, followed by 8 mg every 12 hours for a maximum of 5 days to protect against delayed or prolonged emesis.</p><p><em>For highly emetogenic chemotherapy</em>: a single dose of up to 24 mg Zemitron taken with 12 mg oral dexamethasone sodium phosphate, 1 to 2 hours before chemotherapy, may be used.</p><p>To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal treatment with ondansetron may be continued for up to 5 days after a course of treatment.</p><p>The recommended dose for oral administration is 8 mg to be taken twice daily.</p><p><u>Paediatric population:</u></p><p><em>CINV in children and adolescents (aged 6 months to 17 years)</em></p><p>The dose for CINV can be calculated based on body surface area (BSA) or weight &ndash; see below. In paediatric clinical studies, ondansetron was given by IV infusion diluted in 25 to 50 ml of saline or other compatible infusion fluid and infused over not less than 15 minutes.</p><p>Weight-based dosing results in higher total daily doses compared to BSA-based dosing (see section 4.4).</p><p>There are no data from controlled clinical trials on the use of ondansetron in the prevention of delayed or prolonged CINV. There are no data from controlled clinical trials on the use of ondansetron for radiotherapy-induced nausea and vomiting in children.</p><ul><li>Dosing by BSA:</li></ul><p>Ondansetron should be administered immediately before chemotherapy as a single intravenous dose of 5 mg/m<sup>2</sup>. The single intravenous dose must not exceed 8 mg.</p><p>Oral dosing can commence 12 hours later and may be continued for up to 5 days (Table 1).</p><p>The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p>Table 1: BSA-based dosing for CINV (aged &ge; 6 months to 17 years)</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>BSA</p></td><td style="vertical-align:top"><p>Day 1&nbsp;<sup>(a,b)</sup></p></td><td style="vertical-align:top"><p>Days 2-6&nbsp;<sup>(b)</sup></p></td></tr><tr><td style="vertical-align:top"><p>&lt; 0.6 m<sup>2</sup></p></td><td style="vertical-align:top"><p>5 mg/m<sup>2</sup>&nbsp;IV plus</p><p>2 mg syrup after 12 hours</p></td><td style="vertical-align:top"><p>2 mg syrup every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 0.6 m<sup>2</sup>&nbsp;to &le; 1.2 m<sup>2</sup></p></td><td style="vertical-align:top"><p>5 mg/m<sup>2</sup>&nbsp;IV plus</p><p>4 mg syrup or tablet after 12 hours</p></td><td style="vertical-align:top"><p>4 mg syrup or tablet every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 1.2 m<sup>2</sup></p></td><td style="vertical-align:top"><p>5 mg/m<sup>2</sup>&nbsp;or 8 mg IV plus</p><p>8 mg syrup or tablet after 12 hours</p></td><td style="vertical-align:top"><p>8 mg syrup or tablet every 12 hours</p></td></tr></tbody></table><p>a The intravenous dose must not exceed 8 mg.</p><p>b The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg</p><ul><li>Dosing by bodyweight:</li></ul><p>Weight-based dosing results in higher total daily doses compared to BSA-based dosing (see sections 4.4. and 5.1).</p><p>Ondansetron should be administered immediately before chemotherapy as a single intravenous dose of 0.15 mg/kg. The single intravenous dose must not exceed 8 mg. Two further intravenous doses may be given in 4-hourly intervals.</p><p>Oral dosing can commence 12 hours later and may be continued for up to 5 days (Table 2).</p><p>The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p>Table 2: Weight-based dosing for CINV (aged 6 months to 17 years)</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Body Weight</p></td><td style="vertical-align:top"><p>Day 1<sup>&nbsp;(a,b)</sup></p></td><td style="vertical-align:top"><p>Days 2-6&nbsp;<sup>(b)</sup></p></td></tr><tr><td style="vertical-align:top"><p>&le; 10 kg</p></td><td style="vertical-align:top"><p>Up to 3 doses of 0.15 mg/kg IV every 4 hours</p></td><td style="vertical-align:top"><p>2 mg syrup every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 10 kg</p></td><td style="vertical-align:top"><p>Up to 3 doses of 0.15 mg/kg IV every 4 hours</p></td><td style="vertical-align:top"><p>4 mg syrup or tablet every 12 hours</p></td></tr></tbody></table><p>a The intravenous dose must not exceed 8 mg.</p><p>b The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p><u>Elderly:</u></p><p>No alteration of oral dose or frequency of administration is required.</p><p><u>Patients with renal impairment:</u></p><p>No alteration of daily dosage or frequency of dosing, or route of administration are required.</p><p><u>Patients with hepatic impairment:</u></p><p>Clearance of ondansetron is significantly reduced and serum half-life significantly prolonged in subjects with moderate or severe impairment of hepatic function. In such patients a total daily dose of 8 mg should not be exceeded.</p><p><u>Patients with poor Sparteine/Debrisoquine metabolism:</u></p><p>The elimination half-life of ondansetron is not altered in subjects classified as poor metabolisers of sparteine and debrisoquine. Consequently in such patients repeat dosing will give drug exposure levels no different from those of the general population. No alteration of daily dosage or frequency of dosing is required.</p><p><strong>Post operative nausea and vomiting (PONV)</strong></p><p><u>Adults:</u></p><p><em>For the prevention of PONV,</em> ondansetron can be administered orally or by intravenous or intramuscular injection.</p><p>The recommended oral dose is 16 mg taken one hour prior to anaesthesia.</p><p><em>For the treatment of established PONV,&nbsp;</em>intravenous or intramuscular administration is recommended.</p><p><u>Paediatric population:</u></p><p><em>PONV in children and adolescents (aged 1 month to 17 years)</em></p><ul><li>Oral formulation:</li></ul><p>No studies have been conducted on the use of orally administered ondansetron in the prevention or treatment of post-operative nausea and vomiting; slow IV injection (not less than 30 seconds) is recommended for this purpose.</p><ul><li>Injection:</li></ul><p>For prevention of PONV in paediatric patients having surgery performed under general anaesthesia, a single dose of ondansetron may be administered by slow intravenous injection (not less than 30 seconds) at a dose of 0.1 mg/kg up to a maximum of 4 mg either prior to, at or after induction of anaesthesia.</p><p>For the treatment of PONV after surgery in paediatric patients having surgery performed under general anaesthesia, a single dose of ondansetron may be administered by slow intravenous injection (not less than 30 seconds) at a dose of 0.1 mg/kg up to a maximum of 4 mg.</p><p>There are no data on the use of ondansetron in the treatment of PONV in children below 2 years of age.</p><p><u>Elderly:</u></p><p>There is limited experience in the use of ondansetron in the prevention and treatment of post-operative nausea and vomiting in the elderly, however ondansetron is well tolerated in patients over 65 years receiving chemotherapy<strong>.</strong></p><p><u>Patients with renal impairment:</u></p><p>No alteration of daily dosage or frequency of dosing, or route of administration are required.</p><p><u>Patients with hepatic impairment:</u></p><p>Clearance of ondansetron is significantly reduced and serum half life significantly prolonged in subjects with moderate or severe impairment of hepatic function. In such patients a total daily dose of 8 mg should not be exceeded.</p><p><u>Patients with poor Sparteine/Debrisoquine metabolism:</u></p><p>The elimination half-life of ondansetron is not altered in subjects classified as poor metabolisers of sparteine and debrisoquine. Consequently in such patients repeat dosing will give drug exposure levels no different from those of the general population. No alteration of daily dosage or frequency of dosing is required.</p><p><strong><em>Method of administration</em></strong></p><p>The tablets should be swallowed whole with liquid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Concomitant use with apomorphine is contraindicated (see section 4.5 interactions).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5HT<sub>3</sub>&nbsp;receptor antagonists. Respiratory events should be treated symptomatically and clinicians should pay particular attention to them as precursors of hypersensitivity reactions.</p><p>Ondansetron prolongs the QT interval in a dose-dependent manner (see section 5.1). In addition, post- marketing cases of Torsade de Pointes have been reported in patients using ondansetron. Avoid ondansetron in patients with congenital long QT syndrome. Ondansetron should be administered with caution to patients who have or may develop prolongation of QTc, including patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias or patients taking other medicinal products that lead to QT prolongation or electrolyte abnormalities.</p><p>Hypokalaemia and hypomagnesaemia should be corrected prior to ondansetron administration.</p><p>There have been post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use of ondansetron and other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRI) and serotonin noradrenaline reuptake inhibitors (SNRIs)) (see section 4.5). If concomitant treatment with ondansetron and other serotonergic drugs is clinically warranted, appropriate observation of the patient is advised.</p><p>As ondansetron is known to increase large bowel transit time, patients with signs of subacute intestinal obstruction should be monitored following administration.</p><p>In patients with adenotonsillar surgery prevention of nausea and vomiting with ondansetron may mask occult bleeding. Therefore, such patients should be followed carefully after ondansetron.</p><p>Patients with rare hereditary problems of galactose intolerance, Lapp lactase-deficiency or glucose- galactose malabsorption should not take this medicine.</p><p><strong>Paediatric population</strong></p><p>Paediatric patients receiving ondansetron with hepatotoxic chemotherapeutic agents should be monitored closely for impaired hepatic function.</p><p><strong>CINV</strong></p><p>When calculating the dose on an mg/kg basis and administering three doses at 4-hour intervals, the total daily dose will be higher than if one single dose of 5 mg/m<sup>2</sup>&nbsp;followed by an oral dose is given. The comparative efficacy of these two different dosing regimens has not been investigated in clinical trials. Cross-trial comparison indicates similar efficacy for both regimens (see section 5.1).</p><p><strong>Zemitron contains lactose monohydrate and sodium</strong></p><p>Zemitron contains lactose monohydrate. Each film-coated tablet contains 47.8 mg lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>Zemitron contains sodium. Each film-coated tablet contains 0.175 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence that ondansetron either induces or inhibits the metabolism of other drugs commonly coadministered with it. Specific studies have shown that there are no interactions when ondansetron is administered with alcohol, temazepam, furosemide, alfentanil, tramadol, morphine, lidocaine, thiopental, or propofol.</p><p>Ondansetron is metabolised by multiple hepatic cytochrome P-450 enzymes: CYP3A4, CYP2D6 and CYP1A2. Due to the multiplicity of metabolic enzymes capable of metabolising ondansetron, enzyme inhibition or reduced activity of one enzyme (e.g. CYP2D6 genetic deficiency) is normally compensated by other enzymes and should result in little or no significant change in overall ondansetron clearance or dose requirement.</p><p>Caution should be exercised when ondansetron is coadministered with drugs that prolong the QT interval and/or cause electrolyte abnormalities (see section 4.4).</p><p>Use of ondansetron with QT prolonging drugs may result in additional QT prolongation. Concomitant use of ondansetron with cardiotoxic drugs (e.g. anthracyclines (such as doxorubicin, daunorubicin) or trastuzumab), antibiotics (such as erythromycin), antifungals (such as ketoconazole), antiarrhythmics (such as amiodarone) and beta blockers (such as atenolol or timolol) may increase the risk of arrhythmias. (See section 4.4).</p><p><em>Serotonergic drugs (e.g. SSRIs and SNRIs):</em>&nbsp;There have been post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use of ondansetron and other serotonergic drugs (including SSRIs and SNRIs) (see section 4.4).</p><p><em>Apomorphine:&nbsp;</em>Based on reports of profound hypotension and loss of consciousness when ondansetron was administered with apomorphine hydrochloride, concomitant use with apomorphine is contraindicated.</p><p><em>Phenytoin, Carbamazepine and Rifampicin:</em>&nbsp;In patients treated with potent inducers of CYP3A4 (i.e. phenytoin, carbamazepine, and rifampicin), the oral clearance of ondansetron was increased and ondansetron blood concentrations were decreased.</p><p><em>Tramadol:</em>&nbsp;Data from small studies indicate that ondansetron may reduce the analgesic effect of tramadol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Women of childbearing potential</strong></p><p>Women of childbearing potential should consider the use of contraception.</p><p><strong>Pregnancy</strong></p><p>Based on human experience from epidemiological studies, ondansetron is suspected to cause orofacial malformations when administered during the first trimester of pregnancy.</p><p>In one cohort study including 1.8 million pregnancies, first trimester ondansetron use was associated with an increased risk of oral clefts (3 additional cases per 10 000 women treated; adjusted relative risk, 1.24, (95% CI 1.03-1.48)).</p><p>The available epidemiological studies on cardiac malformations show conflicting results.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>Ondansetron should not be used during the first trimester of pregnancy.</p><p><strong>Breast-feeding</strong></p><p>Tests have shown that ondansetron passes into the milk of lactating animals. It is therefore recommended that mothers receiving Zemitron should not breast-feed their babies.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>There is no information on the effects of ondansetron on human fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zofran has no or negligible influence on the ability to drive and use machines.</p><p>In psychomotor testing ondansetron does not impair performance nor cause sedation. No detrimental effects on such activities are predicted from the pharmacology of ondansetron</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Tabulated list of adverse reactions</strong></p><p>Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000). Very common, common and uncommon events were generally determined from clinical trial data. The incidence in placebo was taken into account. Rare and very rare events were generally determined from post-marketing spontaneous data.</p><p>The following frequencies are estimated at the standard recommended doses of ondansetron. The adverse event profiles in children and adolescents were comparable to that seen in adults.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Immediate hypersensitivity reactions sometimes severe, including anaphylaxis.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Headache.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Seizures, movement disorders (including extrapyramidal reactions such as dystonic reactions, oculogyric crisis and dyskinesia)&nbsp;<sup>(1)</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Dizziness predominantly during rapid IV administration.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Transient visual disturbances (eg. blurred vision) predominantly during IV administration.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Transient blindness predominantly during IV administration&nbsp;<sup>(2)</sup>.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Arrhythmias, chest pain with or without ST segment depression, bradycardia.</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>QTc prolongation (including Torsade de Pointes).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Sensation of warmth or flushing.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hypotension.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hiccups.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Constipation.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Asymptomatic increases in liver function tests&nbsp;<sup>(3)</sup>.</p></td></tr></tbody></table><p>1. Observed without definitive evidence of persistent clinical sequelae.</p><p>2. The majority of the blindness cases reported resolved within 20 minutes. Most patients had received chemotherapeutic agents, which included cisplatin. Some cases of transient blindness were reported as cortical in origin.</p><p>3. These events were observed commonly in patients receiving chemotherapy with cisplatin.</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms and signs</strong></p><p>There is limited experience of ondansetron overdose. In the majority of cases, symptoms were similar to those already reported in patients receiving recommended doses (see section 4.8). Manifestations that have been reported include visual disturbances, severe constipation, hypotension and a vasovagal episode with transient second-degree AV block.</p><p>Ondansetron prolongs the QT interval in a dose-dependent fashion. ECG monitoring is recommended in cases of overdose.</p><p><strong>Paediatric population</strong></p><p>Paediatric cases consistent with serotonin syndrome have been reported after inadvertent oral overdoses of ondansetron (exceeded estimated ingestion of 4 mg/kg) in infants and children aged 12 months to 2 years.</p><p><strong>Management</strong></p><p>There is no specific antidote for ondansetron, therefore in all cases of suspected overdose, symptomatic and supportive therapy should be given as appropriate.</p><p>Further management should be as clinically indicated or as recommended by the national poisons centre, where available.</p><p>The use of ipecacuanha to treat overdose with ondansetron is not recommended, as patients are unlikely to respond due to the anti-emetic action of ondansetron itself.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Serotonin (5HT3) antagonist, ATC code: A04AA01</p><p><strong>Mechanism of action</strong></p><p>Ondansetron is a potent, highly selective 5HT3 receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5HT3 receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system.</p><p>The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.</p><p>Ondansetron does not alter plasma prolactin concentrations.</p><p><strong>Clinical safety and efficacy</strong></p><p>The role of ondansetron in opiate-induced emesis is not yet established.</p><p><strong>QT prolongation</strong></p><p>The effect of ondansetron on the QTc interval was evaluated in a double blind, randomized, placebo and positive (moxifloxacin) controlled, crossover study in 58 healthy adult men and women.</p><p>Ondansetron doses included 8 mg and 32 mg infused intravenously over 15 minutes. At the highest tested dose of 32 mg, the maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction was 19.6 (21.5) msec. At the lower tested dose of 8 mg, the maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction was 5.8 (7.8) msec. In this study, there were no QTcF measurements greater than 480 msec and no QTcF prolongation was greater than 60 msec.</p><p><strong>Paediatric population</strong></p><p><em>CINV</em></p><p>The efficacy of ondansetron in the control of emesis and nausea induced by cancer chemotherapy was assessed in a double-blind randomised trial in 415 patients aged 1 to 18 years (S3AB3006). On the days of chemotherapy, patients received either ondansetron 5 mg/m<sup>2</sup>&nbsp;intravenous and ondansetron 4 mg orally after 8 to 12 hours or ondansetron 0.45 mg/kg intravenous and placebo orally after 8 to 12 hours. Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 3 days. Complete control of emesis on worst day of chemotherapy was 49% (5 mg/m<sup>2</sup>&nbsp;intravenous and ondansetron 4 mg orally) and 41% (0.45 mg/kg intravenous and placebo orally). Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 3 days. There was no difference in the overall incidence or nature of adverse events between the two treatment groups.</p><p>A double-blind randomised placebo-controlled trial (S3AB4003) in 438 patients aged 1 to 17 years demonstrated complete control of emesis on worst day of chemotherapy in:</p><ul><li>73% of patients when ondansetron was administered intravenously at a dose of 5 mg/m<sup>2</sup>&nbsp;intravenous together with 2 to 4 mg dexamethasone orally</li><li>71% of patients when ondansetron was administered as syrup at a dose of 8 mg together with 2 to 4 mg dexamethasone orally on the days of chemotherapy.</li></ul><p>Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 2 days. There was no difference in the overall incidence or nature of adverse events between the two treatment groups.</p><p>The efficacy of ondansetron in 75 children aged 6 to 48 months was investigated in an open-label, non-comparative, single-arm study (S3A40320). All children received three 0.15 mg/kg doses of intravenous ondansetron, administered 30 minutes before the start of chemotherapy and then at 4 and 8 hours after the first dose. Complete control of emesis was achieved in 56% of patients.</p><p>Another open-label, non-comparative, single-arm study (S3A239) investigated the efficacy of one intravenous dose of 0.15 mg/kg ondansetron followed by two oral ondansetron doses of 4 mg for children aged &lt; 12 years and 8 mg for children aged &ge; 12 years (total no. of children n = 28). Complete control of emesis was achieved in 42% of patients.</p><p><em>PONV</em></p><p>The efficacy of a single dose of ondansetron in the prevention of post-operative nausea and vomiting was investigated in a randomised, double-blind, placebo-controlled study in 670 children aged 1 to 24 months (post-conceptual age &ge; 44 weeks, weight &ge; 3 kg). Included subjects were scheduled to undergo elective surgery under general anaesthesia and had an ASA status &le; III. A single dose of ondansetron 0.1 mg/kg was administered within five minutes following induction of anaesthesia. The proportion of subjects who experienced at least one emetic episode during the 24-hour assessment period (ITT) was greater for patients on placebo than those receiving ondansetron (28% vs. 11%, p &lt;0.0001).</p><p>Four double-blind, placebo-controlled studies have been performed in 1469 male and female patients (2 to 12 years of age) undergoing general anaesthesia. Patients were randomised to either single intravenous doses of ondansetron (0.1 mg/kg for paediatric patients weighing 40 kg or less, 4 mg for paediatric patients weighing more than 40 kg; number of patients = 735) or placebo (number of patients = 734). Study drug was administered over at least 30 seconds, immediately prior to or following anaesthesia induction. Ondansetron was significantly more effective than placebo in preventing nausea and vomiting. The results of these studies are summarised in Table 3.</p><p>Table 3: Prevention and treatment of PONV in paediatric patients &ndash; Treatment response over 24 hours</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Study</p></td><td style="vertical-align:top"><p>Endpoint</p></td><td style="vertical-align:top"><p>Ondansetron %</p></td><td style="vertical-align:top"><p>Placebo %</p></td><td style="vertical-align:top"><p>p value</p></td></tr><tr><td style="vertical-align:top"><p>S3A380</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>&le;0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3GT09</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>&le;0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3A381</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>&le;0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3GT11</p></td><td style="vertical-align:top"><p>no nausea</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>0.004</p></td></tr><tr><td style="vertical-align:top"><p>S3GT11</p></td><td style="vertical-align:top"><p>no emesis</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>0.004</p></td></tr></tbody></table><p>CR = no emetic episodes, rescue or withdrawal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Following oral administration, ondansetron is passively and completely absorbed from the gastrointestinal tract and undergoes first pass metabolism. Peak plasma concentrations of about 30 ng/ml are attained approximately 1.5 hours after an 8 mg dose. For doses above 8 mg the increase in ondansetron systemic exposure with dose is greater than proportional; this may reflect some reduction in first pass metabolism at higher oral doses. Mean bioavailability in healthy male subjects, following the oral administration of a single 8 mg tablet, is approximately 55 to 60%. Bioavailability, following oral administration, is slightly enhanced by the presence of food but unaffected by antacids.</p><p>The disposition of ondansetron following oral, intramuscular (IM) and intravenous (IV) dosing is similar with a terminal half life of about 3 hours and steady state volume of distribution of about 140 L. Equivalent systemic exposure is achieved after IM and IV administration of ondansetron.</p><p>A 4 mg intravenous infusion of ondansetron given over 5 minutes results in peak plasma concentrations of about 65 ng/ml. Following intramuscular administration of ondansetron, peak plasma concentrations of about 25 ng/ml are attained within 10 minutes of injection.</p><p>Following administration of ondansetron suppository, plasma ondansetron concentrations become detectable between 15 and 60 minutes after dosing. Concentrations rise in an essentially linear fashion, until peak concentrations of 20-30 ng/ml are attained, typically 6 hours after dosing. Plasma concentrations then fall, but at a slower rate than observed following oral dosing due to continued absorption of ondansetron. The absolute bioavailability of ondansetron from the suppository is approximately 60% and is not affected by gender. The half life of the elimination phase following suppository administration is determined by the rate of ondansetron absorption, not systemic clearance and is approximately 6 hours. Females show a small, clinically insignificant, increase in half-life in comparison with males.</p><p><strong>Distribution</strong></p><p>Ondansetron is not highly protein bound (70-76%).</p><p><strong>Biotransformation and&nbsp;Elimination</strong></p><p>Ondansetron is cleared from the systemic circulation predominantly by hepatic metabolism through multiple enzymatic pathways. Less than 5% of the absorbed dose is excreted unchanged in the urine. The absence of the enzyme CYP2D6 (the debrisoquine polymorphism) has no effect on ondansetron&#39;s pharmacokinetics. The pharmacokinetic properties of ondansetron are unchanged on repeat dosing.</p><p><strong>Special patient populations</strong></p><p><em>Gender</em></p><p>Gender differences were shown in the disposition of ondansetron, with females having a greater rate and extent of absorption following an oral dose and reduced systemic clearance and volume of distribution (adjusted for weight).</p><p><em>Children and Adolescents (aged 1 month to 17 years)</em></p><p>In paediatric patients aged 1 to 4 months (n=19) undergoing surgery, weight normalised clearance was approximately 30% slower than in patients aged 5 to 24 months (n=22) but comparable to the patients aged 3 to 12 years. The half-life in the patient population aged 1 to 4 month was reported to average 6.7 hours compared to 2.9 hours for patients in the 5 to 24 month and 3 to 12 year age range. The differences in pharmacokinetic parameters in the 1 to 4 month patient population can be explained in part by the higher percentage of total body water in neonates and infants and a higher volume of distribution for water soluble drugs like ondansetron.</p><p>In paediatric patients aged 3 to 12 years undergoing elective surgery with general anaesthesia, the absolute values for both the clearance and volume of distribution of ondansetron were reduced in comparison to values with adult patients. Both parameters increased in a linear fashion with weight and by 12 years of age, the values were approaching those of young adults. When clearance and volume of distribution values were normalised by body weight, the values for these parameters were similar between the different age group populations. Use of weight-based dosing compensates for age- related changes and is effective in normalising systemic exposure in paediatric patients.</p><p>Population pharmacokinetic analysis was performed on 428 subjects (cancer patients, surgery patients and healthy volunteers) aged 1 month to 44 years following intravenous administration of ondansetron. Based on this analysis, systemic exposure (AUC) of ondansetron following oral or IV dosing in children and adolescents was comparable to adults, with the exception of infants aged 1 to 4 months. Volume was related to age and was lower in adults than in infants and children. Clearance was related to weight but not to age with the exception of infants aged 1 to 4 months. It is difficult to conclude whether there was an additional reduction in clearance related to age in infants 1 to 4 months or simply inherent variability due to the low number of subjects studied in this age group. Since patients less than 6 months of age will only receive a single dose in PONV a decreased clearance is not likely to be clinically relevant.</p><p><em>Elderly</em></p><p>Early Phase I studies in healthy elderly volunteers showed a slight age-related decrease in clearance, and an increase in half-life of ondansetron. However, wide inter-subject variability resulted in considerable overlap in pharmacokinetic parameters between young (&lt; 65 years of age) and elderly subjects (&ge; 65 years of age) and there were no overall differences in safety or efficacy observed between young and elderly cancer patients enrolled in CINV clinical trials to support a different dosing recommendation for the elderly.</p><p>Based on more recent ondansetron plasma concentrations and exposure-response modelling, a greater effect on QTcF is predicted in patients &ge;75 years of age compared to young adults. Specific dosing information is provided for patients over 65 years of age and over 75 years of age for intravenous dosing.</p><p><em>Renal impairment</em></p><p>In patients with renal impairment (creatinine clearance 15-60 ml/min), both systemic clearance and volume of distribution are reduced following IV administration of ondansetron, resulting in a slight, but clinically insignificant, increase in elimination half-life (5.4 hours). A study in patients with severe renal impairment who required regular haemodialysis (studied between dialyses) showed ondansetron&#39;s pharmacokinetics to be essentially unchanged following IV administration.</p><p><em>Hepatic impairment</em></p><p>Following oral, intravenous or intramuscular dosing in patients with severe hepatic impairment, ondansetron&#39;s systemic clearance is markedly reduced with prolonged elimination half-lives (15-32 hours) and an oral bioavailability approaching 100% due to reduced pre-systemic metabolism. The pharmacokinetics of ondansetron following administration as a suppository have not been evaluated in patients with hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Embryo-fetal development studies in rats and rabbits did not show evidence of harm to the fetus when ondansetron was administered during the period of organogenesis at approximately 6 and 24 times respectively the maximum recommended human oral dose of 24 mg/day, based on body surface area. In a pre- and postnatal developmental toxicity study, there were no effects upon pregnant rats and the pre- and postnatal development of their offspring, including reproductive performance at approximately 6 times the maximum recommended human oral dose of 24 mg/day based on body surface area.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; Lactose monohydrate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Microcrystalline cellulose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Sodium starch glycolate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Magnesium stearate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Hydroxypropyl methyl cellulose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Titanium dioxide</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Pigment blend yellow</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Yellow iron oxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a dry place below 30&deg;C.</p><p>Store in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum-aluminum blisters.</p><p>Pack size: 10 Film-coated Tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None stated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Arab Pharmaceutical Manufacturing PSC
P.O. Box 42
Sult, Jordan
Tel: + (962-5) 3492200
Fax: + (962-5) 3492203
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 May 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>